Tuberculosis control policies in major metropolitan health departments in the United States. V. Standard of practice in 1992.
Since 1978, we have surveyed the 28 metropolitan health departments initially reporting > 250 cases of tuberculosis/yr to determine the standard of practice in the control of pulmonary tuberculosis and the factors affecting treatment policy. In this survey, results were compared with data obtained in 1978, 1980, 1984, and 1988. As in the previous years, all departments completed the survey. The predominant treatment regimen was 6 months of chemotherapy (64 +/- 1.33% of patients) involving isoniazid (I), rifampin (R), and pyrazinamide (Z). Estimated duration of treatment, which had decreased from 20.2 +/- 2.1 months in 1980 to 7.58 +/- 1.02 months in 1988, increased to 9.34 +/- 2.32 months in 1992 (p < 0.01). This was attributed to an increase in drug-resistant cases (17 of 25 programs) and to increased incidence of HIV infection during the previous 4 yr. In 1984, HIV infection was estimated to coincide with tuberculosis in 2.54% of all patients, 7.72% in 1988, and 17.42% in 1992. Several other major departures from prior perceived practices were reported. In 1980, 32.1% of all patients were hospitalized initially for tuberculosis treatment, and this number decreased progressively to 17.8% in 1988; in 1992, 34.2 +/- 1.32% of patients with tuberculosis were hospitalized for initial treatment. In 1988, no program reported regular use of alternative therapy to isoniazid for chemoprophylaxis; in 1992, 21 programs used alternative regimens (predominantly R-containing). In 1992, nine programs reported increased funds for treatment of tuberculosis (27.2 +/- 1.97% after inflation), whereas 16 reported a mean decrease of 14% after inflation.(ABSTRACT TRUNCATED AT 250 WORDS)
Leff
D R
DR
Center for Urban Affairs and Policy Research, Northwestern University, Evanston, Illinois.
Leff
A R
AR
D017088:AIDS-Related Opportunistic Infections / Q000517:prevention & control; D000328:Adult; D000995:Antitubercular Agents / Q000008:administration & dosage; D002648:Child; D003625:Data Collection; D015658:HIV Infections / Q000150:complications; D006291:Health Policy; D006801:Humans; D011635:Public Health Administration; D014397:Tuberculosis, Pulmonary / Q000150:complications / Q000188:drug therapy* / Q000517:prevention & control*; D014481:United States; D014504:Urban Health
D000995:Antitubercular Agents